Categories
Tag Cloud
aal aerospace africa ageing agriculture asia astronomy australia austria bacteria batteries belgium biology business cancer chemistry children china cities climate cloud collaboration communication computing conference conservation construction consumers copenhagen summit cyprus czech republic data denmark digital discovery disease dna drugs earth sciences ec economy education electronics energy environment erc esa eu europe family finland food fp7 france fraunhofer funding future future internet gender genetics germany global greece green health health and safety healthcare hydrogen ict imaging immune system india industry innovation internet ireland israel italy jrc language large hadron collider lasers manufacturing medicine middle east mobile technology nano nature netherlands networks neurology norway nutrition oceanography pharmacy photonics physics poland policy portugal production psychology research safety science security sensor shipping society solar south america space spain stem cell surgery sustainable sweden switzerland tb technology test theoretical therapy trains transport treatment uk universities urban usa vaccine waste water
Dr Paul Finn
CEO
InhibOx
Dr Paul Finn is the CEO of InhibOx, a pioneering computational drug discovery company based in Oxford, UK. Dr Finn holds a PhD in biochemistry from Manchester University and has worked for Pfizer's computational chemistry group, where he was responsible for developing Pfizer's in-house approach to virtual screening. He is also the lead researcher for the FP6 project DeZnIT.
Email: paul.finn@inhibox.com
Telephone: 0044 (0)1865 262 003
Latest articles by Dr Paul Finn
- Ahead in the cloud - computational drug discovery reaches for the next level
Cloud computing offers the promise of a flexible computing platform for drug discovery researchers, enabling access to technologies previously unavailable, unaffordable or at a scale previously unobtainable.